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Abstract
Glycosylation plays an essential role in regulating protein function by modulating biological,
structural, and therapeutic properties. However, due to its inherent heterogeneity and diversity, the
comprehensive analysis of protein glycosylation remains a challenge. As part of our continuing
effort in the analysis of glycosylation profiles of recombinant HIV-1 envelope-based immunogens,
we evaluated and compared the host-cell specific glycosylation pattern of recombinant HIV-1
surface glycoprotein, gp120, derived from clade C transmitted/founder virus 1086.C expressed in
Chinese hamster ovary (CHO) and human embryonic kidney containing T antigen (293T) cell
lines. We used an integrated glycopeptide-based mass mapping workflow that includes a partial
deglycosylation step described in our previous study1 with the inclusion of the fragmentation
technique, electron transfer dissociation (ETD), to complement collision induced dissociation
(CID). The inclusion of ETD facilitated the analysis by providing additional validation for
glycopeptide identification and expanding the identified glycopeptides to include coverage of O-
linked glycosylation. The site-specific glycosylation analysis shows that the transmitted/founder
1086.C gp120 expressed in CHO and 293T displayed distinct similarities and differences. For N-
linked glycosylation, two sites (N386 and N392), in the V4 region were populated with high
mannose glycans in the CHO cell-derived 1086.C gp120, while these sites had a mixture of high
mannose and processed glycans in the 293T cell-derived 1086.C gp120. Compositional analysis of
O-linked glycans revealed that 293T cell-derived 1086.C gp120 consisted of cores 1, 2, and 4 type
O-linked glycans while CHO cell-derived 1086.C exclusively consisted of core 1 type O-linked
glycans. Overall, glycosylation site occupancy of the CHO and 293T cell-derived 1086.C gp120
show high degree of similarity except for one site at N88 in the C1 region. This site was partially
occupied in 293T-gp120 but fully occupied in CHO-gp120. Site-specific glycopeptide analysis of
transmitted/founder 1086.C gp120 expressed in CHO cells revealed the presence of
phosphorylated glycans while 293T cell produced 1086.C gp120 glycans were not phosphorylated.
While the influence of phosphorylated glycans on immunogenicity is unclear, distinguishing host-
cell specific variations in glycosylation profiles provides insights into the similarity (or difference)
in recombinant vaccine products. While these differences had minimal effect on envelope
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antigenicity, they may be important in considering immunogenicity and functional capacities of
recombinant envelope proteins produced in different expression systems.
Introduction
One of the important considerations in the production of recombinant therapeutic proteins is
the choice of expression system. The choice primarily will depend on whether the
expression system could efficiently produce proteins with desired pharmacological activity
and consistent quality2–6. Most often these criteria are met by expression systems that enable
proper protein folding and have the capacity for post-translational modifications (PTMs), in
particular glycosylation7,8. Glycan modification of proteins influences proper protein
folding and secretion efficiency. In addition, it has a profound effect on the protein’s
therapeutic profile such as efficacy, stability, solubility, biological activity, in vivo half-life,
immunogenicity, and pharmacokinetics9–11. For the production of glycosylated therapeutic
proteins, mammalian cell expression systems are the most suitable choice since they contain
the cellular machinery that permit correct protein folding and glycosylation patterns similar
to those of human cells. While there is currently no consensus on what form and level of
glycosylation is appropriate, a necessary first step to understand the impact of glycosylation
on the protein’s function is to define its overall glycosylation profile.
The task of elucidating the global glycosylation profile of proteins remains an analytical
challenge. The difficulty stems from the inherent heterogeneity of glycans at any given
glycosylation site and variable glycosylation site utilization. Protein glycosylation proceeds
in a series of enzyme processing steps as proteins are secreted in the endoplasmic reticulum
(ER) and progress through the Golgi apparatus4,12,13. For any given protein, the overall
glycosylation profile is determined by the set of complement Golgi-resident enzymes unique
to a specific host cell, tissue, and species as well as dependent on the accessibility of the
potential glycosylation site of the protein in question12,14. Thus, different cell types display
different types of glycosylation. Moreover, glycan synthesis is also affected by the cell
culture conditions and perturbations in the cell environment15–17. Despite this inherent
heterogeneity and diversity, recent technological advances in analytical methodologies have
provided unprecedented means to effectively characterize protein glycosylation18–21.
Among the analytical methodologies that are routinely employed in the analysis of protein
glycosylation, mass spectrometry (MS) is the most widely used, due to its sensitivity and
selectivity18,22,23. The recent technological advances in MS instrumentation, specifically the
availability of multistage fragmentation modes in new generation hybrid mass
spectrometers, along with the advances in sample preparation methods and front-end
separation platforms are enabling more comprehensive methods to effectively analyze
protein glycosylation. There are two common forms of protein glycosylation depending on
their protein linkage- N-linked glycans are attached to asparagine residues in the consensus
sequence, NXT/S, where X can be any amino acid except proline while O-linked glycans are
attached to the hydroxyl group of threonine or serine residues. MS characterization of N- or
O- linked protein glycosylation is typically accomplished by analysis of the enzymatically or
chemically released glycans for protein-specific information, or by glycopeptide-based MS
analysis for glycosylation-site specific information21,23,24. To fully characterize the
glycosylation profile of a given glycoprotein, especially for those with multiple
glycosylation sites, it is critical to determine the glycan motifs as well as the extent of
glycosylation at each potential glycosylation site, because changes in glycosylation in one of
the sites could dramatically impact both protein structure and function. Such analysis would
necessitate a glycopeptide-based MS analysis. In a typical workflow, glycoproteins are
digested with a specific or non-specific protease to generate peptide/glycopeptide mixture
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that is subsequently subjected to separation and/or an enrichment step prior to MS and
tandem MS analyses. Glycopeptide compositions are then determined from MS and MS/MS
data with the aid of downstream data analysis tools24–27.
As part of an ongoing effort in the glycosylation analysis of recombinant subunit
immunogens based on the HIV-1 envelope proteins (Envs), we have demonstrated that
optimization and integration of new methods such as partial deglycosylation to facilitate
glycopeptide analysis and thereby markedly improving glycosylation coverage1,25. With the
goal of increasing glycosylation coverage of HIV-1 envelope proteins and providing further
validation of the glycosylation analysis data, we expanded our experimental workflow to
include electron transfer dissociation (ETD), used in tandem with collision induced
dissociation (CID). ETD combines the ability to fragment the peptide backbone while
leaving the glycan modification intact, thus providing unique complementary information to
CID, in which conventional glycosidic cleavages are obtained. To date, the use of CID and
ETD in glycopeptide-based MS analysis is well documented26–31. Using this new
experimental workflow for HIV-1 recombinant envelope analysis, we have determined the
host-cell specific gp120 glycosylation profiles of the recombinant clade C transmitted/
founder virus, 1086.C gp120 expressed in two different cell lines- CHO and 293T. The host-
cell specific HIV-2 gp120 N-glycosylation has been described previously32,33 and most
recently the host-cell specific N-glycosylation of HIV-1 gp120 expressed in eight
mammalian cell lines has been reported21. Host-cell specific glycosylation patterns of HIV-2
gp120 were reported to differ in complex-type glycans32,33 while the overall ratio of high
mannose to complex-type glycans is cell type specific and is dependent on the cell line’s
metabolic state during expression in HIV-1 gp12021. The variation in the ratio of the high
mannose to complex type glycan content in HIV-1 gp120 observed in different mammalian
cell lines was found to influence antibody recognition from polyclonal sera. In all of these
studies, glycosylation analysis was performed using enzymatically released gp120 glycans
and results were based on the overall glycan pool thereby not providing site-specific glycan
differences in terms of the type of glycans and the extent of processing at each potential
glycosylation site. Herein, we present a full site-specific glycosylation MS-based analysis of
the CHO and 293T cell-derived 1086.C gp120 detailing the glycosylation profile at each of
the 23 potential glycosylation sites using the integrated approach described in our previous
study1 with the inclusion of ETD. Site-to-site comparison of the N- and O-linked
glycosylation profiles between the CHO and 293T cell-derived 1086.C gp120 revealed
distinct similarities as well as differences in terms of glycan content. Notably, we identified
the presence of mannose phosphate exclusively for CHO cell-derived 1086.C gp120. In
addition, the O-glycan compositions near the end of the sequence (T499) were elucidated for
the first time for both gp120s and displayed a host-specific glycosylation pattern. We also
evaluated the effect of expression system in antigenicity of the CHO and 293T cell-derived
1086.C gp120. Distinguishing the host-cell specific glycosylation similarities and




Trizma@ hydrochloride, Trizma@ base, ethylenediaminetetraacetic acid (EDTA), HPLC
grade acetonitrile (CH3CN) and methanol (CH3OH), urea, dithiothreitol (DTT), tris(2-
carboxyethyl)phosphine hydrochloride (TCEP), iodoacetamide (IAA), ammonium
hydroxide, glacial acetic acid, and formic acid were purchased from Sigma (St. Louis, MO).
All reagents and buffers were prepared with deionized water purified to at least 18 MΩ with
a Millipore Direct-Q3 Water Purification System (Billerica, MA). Sequencing grade trypsin
(Tp) was obtained from Promega (Madison, WI). Glycerol-free peptidyl-N-glycosidase F
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(PNGase F) cloned from Flavobacterium meningosepticum and endo-β-N-
acetylglucosaminidase H (Endo H) cloned from Streptomyces plicatus, were purchased from
New England BioLabs (Ipswich, MA).
Expression and Purification 1086.C gp120 Proteins
1086.C gp120 proteins were obtained from the Duke Human Vaccine Research Institute in
Durham N.C. The 1086.C gp120 recombinant envelope protein was produced as follows:
The HIV-1 Env gene was codon-optimized by converting amino acid sequences to
nucleotide sequences employing the codon usage of highly expressed human housekeeping
genes and de novo synthesized as gp120. The 1086.C gp120 gene was cloned into a
mammalian expression plasmid pcDNA3.1/hygromycin (Invitrogen, Carlsbad, CA). The
1086.C gp120 was expressed in transiently transfected 293T or CHO cells. Recombinant
Env glycoproteins were purified using Galanthus nivalis lectin-agarose (Vector Labs,
Burlingame, CA) column chromatography from supernatants of 293T or CHO cell cultures,
and further purified on a Superdex S200 size exclusion column (GE Healthcare) to remove
aggregates and dimers. The purified monomeric gp120 was stored at −80°C until use.
Deglycosylation of 1086.C gp120
Samples containing 100 µg gp120 were deglycosylated with either PNGase F or Endo H to
determine the degree of glycosylation site occupancy. For PNGase F treatment, samples
were incubated with 1 µL of PNGase F solution (500,000 units/mL) for a week at 37°C at
pH 7.5. With Endo H treatment, pH of the sample solution was adjusted to pH 5.5 with 200
mM HCl prior to deglycosylation. Samples were then denatured with 2 M urea followed by
the addition of 2 µL of Endo H (≥5 units/mL). After thorough mixing, the reaction was
incubated for 48 hours at 37°C. The pH of the deglycosylated samples was adjusted to 8.0
with 300 mM NH4OH prior to tryptic digestion. Deglycosylated samples were digested with
trypsin as described below.
Digestion of 1086.C gp120
1086.C gp120 samples (100 µg) at a concentration of ~1 mg/mL were denatured with 6 M
urea in 100 mM tris buffer (pH 8.0) containing 3mM EDTA and were fully reduced using 5
mM TCEP at room temperature for one hour. Following reduction, samples were alkylated
with 20 mM IAA at RT for another hour in the dark. Excess IAA in both samples was
quenched by adding DTT to a final concentration of 25 mM and incubated for 20 min at
room temperature. The reduced and alkylated samples were buffer exchanged and
concentrated using a 30 kDa MWCO filter (Millipore, Billerica MA) prior to trypsin
digestion. Samples were subsequently digested with trypsin (30:1 protein:enzyme ratio) at
37°C and incubated overnight, followed by second trypsin addition under the same
conditions. The resulting HIV-1 glycoprotein digest was either directly analyzed or stored at
−20°C until further analysis. To ensure reproducibility of the method, protein digestion was
performed at least three times on different days with samples obtained from the same batch
and analyzed with the same experimental procedure.
Chromatography and Mass Spectrometry
High resolution LC/MS experiments were performed using a hybrid linear quadrupole ion-
trap Fourier transform ion cyclotron resonance mass spectrometer (LTQ-FT, Thermo
Scientific, San Jose, CA) directly coupled to Dionex UltiMate capillary LC system
(Sunnyvale, CA) equipped with a FAMOS well plate autosampler. ETD experiments were
performed on an LTQ-Velos (Thermo Scientific, San Jose, CA) mass spectrometer equipped
with ETD, coupled to a Waters Acquity UltraPerformance (UP) LC system (Bellirica, MA).
In both experiments, mobile phases consisted of solvent A: 99.9% deionized H2O + 0.1%
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formic acid and solvent B: 99.9 % CH3CN + 0.1% formic acid. Five microliters of the
sample (~7 µM) was injected onto C18 PepMap™ 300 column (300 µm i.d. × 15 cm, 300 Å,
LC Packings, Sunnyvale, CA) at a flow rate of 5 µL/min. The following CH3CN/H2O
multistep gradient was used: 5% B for 5 min, followed a linear increase to 40% B in 50 min,
then a linear increase to 90% B in 10 min. The column was held at 95% B for 10 minutes
before re-equilibration. A short wash and blank run were performed between every sample
to ensure no sample carry-over. All mass spectrometric analysis was performed in a data
dependent mode as described below. For the high resolution experiment, the ESI source was
operated in the following conditions: source voltage of 2.8 kV, capillary temperature of
200°C, and capillary offset voltage of 41 V. Data were collected in the positive ion mode.
Data dependent acquisition (DDA) mode was setup to sequentially and dynamically select
five most intense ions in the survey scan at a resolution (R) at 25000 at m/z 400 for
subsequent CID in the LTQ linear ion trap, using a normalized collision energy of 35% and
a 3 minute dynamic exclusion window. Under these conditions, the measured R (FWHM) in
the FT-ICR mass analyzer at m/z 1000 is 10,000 and 6700 at m/z 1500. DDA mode in the
LTQ-Velos was setup in the following manner: A full MS scan using enhanced scan mode
was acquired followed by subsequent MS2 scans depending on the experiment. For ETD
experiments, the five most intense ions from the survey scan were sequentially and
dynamically selected for ETD. For the alternating ETD and CID, DDA was set up to acquire
10 scan events: For every one full MS scan in the mass range, 300–2000 m/z, each selected
m/z in the MS scan were subjected to three MS/MS events- (a) CID, (b) ETD, and (c) CID
of the charge reduced state in the previous ETD event. The mass spectrometric parameters
used for the experiment were: spray voltage 3.0 kV, S-lens RF value between 45–55%,
capillary temperature of 250°C, normalized collision energy of 35% for CID, and the ion-ion
reaction time of 100–150 msec.
Glycopeptide Identification
Data were analyzed using a combination of freely available web-based informatics tools,
GlycoPep DB34, GlycoPep ID35, GlycoMod36, and Protein Prospector (http://
prospector.ucsf.edu). Data acquired on the LTQ-FT were analyzed using GlycoPep DB,
GlycoPep ID, and GlycoMod. Details of the compositional analysis have been described
previously37–39. Briefly, compositional analysis of glycopeptides with one glycosylation site
was carried out by first identifying the peptide portion from CID data. The peptide portion
was inferred manually or by Glycopep ID from the Y1 ion, a glycosidic bond cleavage
between the two N-acetyl glucosamine at the pentasaccharide core. Once the peptide
sequence is determined, plausible glycopeptide compositions were obtained using the high
resolution MS data and GlycoPep DB, and the putative glycan candidate was confirmed
manually by identifying the Y1 ion and inspecting the glycan fragmentation pattern from the
tandem MS data. For glycopeptides with multiple glycosylation sites, experimental masses
of glycopeptide ions from the high resolution MS data were converted to singly charged
masses and submitted to GlycoMod. This program calculates plausible glycopeptide
compositions from the set of experimental mass values entered by the user and compares
these mass values with theoretical mass values, then generated a list of plausible
glycopeptide compositions within a specified mass error. Plausible glycopeptide
compositions in GlycoMod were deduced by providing the mass of the singly charged
glycopeptide ion, enzyme, protein sequence, cysteine modification, mass tolerance, and the
possible types of glycans present in the glycopeptide. Plausible glycopeptide compositions
obtained from the analysis were manually confirmed and validated from MS2 data.
Raw data containing mixed CID and ETD spectra acquired using an alternating CID/ETD
scans on the LTQ-Velos were analyzed manually. ETD spectra of glycopeptides identified
from a preceding CID scan were manually assessed for peptide fragment ions using Protein
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Prospector. For each identified glycopeptide from the proceeding CID scan, observed
peptide fragment ions were manually matched to the theoretical peptide fragment ions
generated from Protein Prospector. Matched fragment ions that are within 0.5 Da of the
theoretical value were accepted.
Peptide Identification
Deglycosylated peptides were identified by searching raw data acquired on the hybrid LTQ
FTICR mass spectrometer against a custom HIV database with 148 gp120/gp41 sequences,
obtained from the Los Alamos HIV sequence database (http://www.hiv.lanl.gov/content),
using Mascot (Matrix Science, London, UK, version 2.3.2). The peak list was extracted from
raw files using Mass Matrix conversion tool. Mgf files were searched specifying the
following parameters: (a) enzyme: trypsin, (b) missed cleavage: 2, (c) fixed modification:
carbamidomethyl, (d) variable modification: methionine oxidation, carbamyl, HexNAc, and
dHexNAc (e) peptide tolerance of 0.8 Da, and (f) MS/MS tolerance of 0.4 Da. Peptides
identified from the Mascot search were manually validated from MS2 data to ensure major
fragmentation ions (b and y ions) were observed, especially for peptides generated from
PNGase F treated samples that contain N to D conversions.
Surface plasmon resonance (SPR) binding of gp120 mAbs
Env gp120 binding measurements were carried out on BIAcore 3000 instruments as
described earlier 40–42. The conformational, C1 mAb A32, and sCD4 were directly
immobilized on a CM5 sensor chip using standard amine coupling chemistry, and 1086.C
gp120 were injected at 100 µg/mL for 2 min. Following a brief washing period, the CD4
inducible mAb 17b was injected over both A32 and CD4 captured gp120 surfaces. Binding
responses were calculated using report points at the end of the injection period. For
measuring the binding of all other gp120 mAbs, anti-human IgG Fc antibody (Sigma
Chemicals) was immobilized on a CM5 sensor chip to about 15000 Response Unit (RU),
and each antibody was captured to about 50–100 RU and binding of 1086.C gp120 (100 µg/
mL) was monitored as described above. An adjacent flow cell with the Synagis mAb (anti-
RSV) was used as control. Non-specific binding of 1086.C gp120 to the control surface was
subtracted for each mAb-gp120 binding interactions. All data analysis was performed using
the BIAevaluation 4.1 analysis software (GE Healthcare).
Results and Discussion
Site-Specific Glycosylation Analysis of 1086.C gp120
The 1086.C gp120 immunogens were stably expressed and purified as monomers in 293T
and CHO cell lines from a vector encoding gp120 derived from an African clade C early
transmitted/founder virus43. This protein has 23 potential N-linked glycosylation (PNG)
sites, of which 12 are located in the conserved regions, C1-C5, and 11 are in the variable
regions, V1-V5 (Figure 1). The glycosylation profile on each of the 23 potential N-linked
sites was determined using an integrated glycopeptide-based MS workflow described in our
previous study1 with the inclusion of ETD. ETD offers the advantage of obtaining extensive
peptide sequence information while leaving labile modifications intact. In a typical analysis,
1086.C gp120s were digested with trypsin or treated with glycosidases PNGase F or Endo H
prior to trypsin digestion using in-solution digestion and were subsequently analyzed by LC/
ESI FTICR MS. Once high resolution data was acquired, samples were analyzed using
LTQ-Velos equipped with ETD using the same column and gradient. Figure 2A shows
representative high resolution MS1 data obtained from the high resolution measurement and
the corresponding CID data (Fig 2B). Figure 2C shows the representative ETD data of the
same sample analyzed on the LTQ-Velos. The composition of the set of glycopeptides
eluting at a given retention time window in the high resolution measurement such as shown
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in Figure 2A were determined from the fragment mass information obtained from CID
analysis with the additional available information from ETD analysis. As an example,
assignment of a putative biantennary complex-type glycopeptide containing the peptide
portion, , from the CID and ETD spectra is illustrated in Figures 2B
and 2C. The CID spectrum (Fig. 2B) of the doubly charged complex-type glycopeptide at m/
z 1730, which is dominated by ions corresponding to a series of glycosidic bond cleavages
resulting from the losses of monosaccharide units, is used to assign the glycan component of
the glycopeptide. Also observed in the CID spectrum is a set of ions consisting of the
following: (a) one of the characteristic glycopeptide marker ions at m/z 528, (b) the
glycosidic cleavage ion Y1 ion at m/z’s 1894 (1+) and 947 (2+), from which the peptide
portion was deduced, (c) a few y-type ions resulting from the peptide backbone cleavage at
m/z’s 586 (y5),704 (y6), and 817 (y7), and (d) ions at m/z 1690 (1+) and 946 (2+)
corresponding to the m/z of the peptide portion. It is worth noting that the presence of the
ions at m/z 1690 (1+) and 946 (2+) provided confirmatory information for the assignment of
the peptide portion. While this information is usually adequate and effective to deduce the
peptide portion of the glycopeptide, CID data provides limited peptide fragment ions, which
are needed when the Y1 ion is not easily identified in the CID spectrum or when the Y1 ion
corresponds to two isobaric glycopeptides with different peptide portions. In these cases,
ETD analysis is very helpful because extensive peptide backbone fragment ions are
observed. The ETD spectrum of the triply charged ion of the same glycopeptide, in Fig. 2C,
shows a contiguous fragment ion series, c3–12 and z4–14, confirming the initial peptide
assignment inferred from CID. Once the peptide portion was identified, the composition of
the glycopeptide peaks in Fig. 2A containing the peptide portion, ,
were determined using GlycoPep DB and GlycoMod. Each assignment was further verified
manually. Aside from the glycopeptides observed in Fig 2A, we also identified a non-
glycosylated peptide, , located in the V5 region, at m/z
1171, coeluting with the glycopeptides. Overall, using the combination of CID and ETD
facilitated the analysis and provided further verification of the glycopeptide identifications
due to the complementary fragmentation information that is obtained. We obtained full
glycosylation coverage for all the 23 potential N-glycosylation sites. A total of ~500 unique
glycopeptide compositions per 1086.C gp120 were identified from this analysis. The
complete list is found in Supplementary Tables 1, 2, 3, and 4.
Glycosylation Site Occupancy of 1086.C gp120 Expressed in CHO versus 293T cells
The main method for determining glycosylation site occupancy was using Endo H digestion
and detection of the products, as we have described previously1. Example data from this
approach are shown in Figures 3A and 3B which contain CID and ETD data respectively,
for an Endo H-treated peptide, , containing two potential
glycosylation sites. After assignment of the b and y ions (in the CID data) or the c and z ions
(in the ETD data) it is clear that this peptide contains one occupied glycosylation site and
one unoccupied site. While determining the site occupancy of glycopeptides by detecting the
deglycosylated products following Endo H treatment was effective for nearly all the PNG
sites, glycopeptides containing processed glycans are not cleaved by Endo H, and therefore,
not detected as deglycosylated products. In these cases, site occupancy could still be
determined, based on the ETD data of the glycopeptide. Two examples are shown in Figures
3C and 3D. In Fig. 3C, the ETD data for a peptide with two PNG sites, , is
used to show that a complex glycan is present at the first site, and the second site is
unoccupied. In Fig. 3D, the ETD data are used to verify that the peptide
, contains a high mannose glycan at the first site, which
has been cleaved by Endo H, and a complex glycan at the second site, which remains intact
after Endo H treatment. Therefore, both sites on this peptide are occupied. Site occupancy
data from the Endo H treated samples were also independently confirmed with analysis
Go et al. Page 7













using PNGase F treatment. All data were searched against an HIV-1 custom database
containing 148 HIV-1 Env sequences as described in the Experimental Section and were
verified manually for further confirmation. Table 1 shows the summary of the degree of
glycosylation site occupancy obtained from the analysis. Comparison of the glycosylation
site occupancy between the 1086.C gp120 expressed from CHO and 293T cell lines revealed
that both 1086.C gp120 samples display a very similar degree of glycosylation site
occupancy except for one PNG site at, N88 in the C1 region. This site is partially utilized for
293T cell-derived 1086.C gp120 but fully occupied in the CHO cell-derived 1086.C gp120.
An Expanded 1086.C gp120 Glycosylation Profile
The complementary nature of CID and ETD facilitated compositional assignment of the
identified N-linked glycopeptides and expanded the glycosylation profiles of 1086.C gp120s
to include O-linked glycosylation. Indeed, the combined use of CID and ETD enabled the
unambiguous identification of an O-linked modified threonine for gp120s produced in both
cell lines. Figures 4A and 4B show representative tandem MS data of a core 2 type O-linked
modified T499. Product ions observed in the CID spectrum of the O-linked glycopeptide at
m/z 644 (3+) consisted of ions from glycosidic bond cleavages, ions corresponding to the
putative non-glycosylated peptide, and the four characteristic oxonium ions of a sialylated
O-linked glycan at m/z 204.2 (N-acetyl hexosamine), 274.2 (sialic acid-H2O), 292.2 (sialic
acid), and 366.1 (hexose-N-acetyl hexosamine). Based on the m/z of the non-glycosylated
peptide in the CID spectrum, we inferred that the O-glycopeptide contains the peptide
portion, . This initial assignment was confirmed with the
corresponding ETD data shown in Fig 4B, wherein almost a complete series of c and z type
fragment ions were observed. In addition, an abundant peak corresponding to glycosidic
bond cleavage due to the loss of a sialic acid at m/z 1142, the charge reduced species, and
small neutral losses due to side chain losses were also observed. From the glycosidic bond
cleavages and the ion corresponding to the peptide portion observed in the CID spectrum as
well as the peptide backbone cleavages observed in the ETD spectrum, it is apparent that the
glycopeptide was modified at T499 with a core 2 type sialylated glycan. Within the retention
time window where the O-linked glycopeptides eluted, we assigned 13 distinct O-linked
glycopeptides for the 293T cell-derived 1086.C gp120 and five O-linked glycopeptides
CHO cell-derived 1086.C gp120, respectively as shown in Table 2. Based on the
glycopeptide compositions that were identified, CHO cell-derived 1086.C gp120 contains
core 1 type O-linked glycopeptides while 293T cell - derived 1086.C gp120 appears to have
cores 1, 2, and 4 type O-linked glycopeptides. In addition, we also identified that the O-
linked modified T499 site is partially occupied as determined from CID and ETD analysis.
O-linked glycans have been recently reported to be expressed on Hendra virus glycoprotein
grown in both HEK293T cells and HeLa cells44.
In addition to the O-linked glycopeptides, we detected the presence of phosphorylated
glycopeptides in the CHO cell-derived 1086.C gp120 digests but not in 293T cell-derived
1086.C gp120. Phosphorylation is known to occur in the peptide backbone, specifically on
serine, threonine, or tyrosine residues as well as on N-linked glycans. Glycosylation analysis
of the CHO cell-derived 1086.C gp120 digest revealed that phosphorylation was localized to
the N-linked glycans as determined by CID and ETD analysis (Fig. 5.) A representative CID
spectrum (Fig. 5A) of the glycopeptide containing the peptide sequence,
, showed the loss of four mannose residues, loss of a phosphate, and
a series of y-type ions (y3–9). It should be noted that peptide sequence contains two
threonine residues and one serine residue that can be potentially phosphorylated. Except for
the threonine near the potential glycosylation site at N197, the series of y-type ions (y3–9) in
the CID spectrum indicate that the neither serine nor threonine residues were modified by
phosphate. Additional information obtained from the ETD spectrum (Fig, 5B) showing the
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contiguous z-type ions (z4–11, 13–14) and c-type ions (c3–6, 14) indicates that the glycans are
modified by phosphate. The fragmentation information obtained from both CID and ETD
were sufficient to identify phosphorylated high mannose and hybrid type glycans on CHO
cell-derived 1086.C gp120 at six glycosylation sites-N130, N137, N187, and N197 in the
V1-V2 region, N276 in the C2 region, and N408 in the V4 region.
Glycan Profile of 1086.C gp120 Expressed in CHO versus 293T cells
From the data reported in this study, as shown in the Supplementary Tables 1 and 2, the
glycans identified for 1086.C gp120 expressed in CHO and 293T cells consisted of a broad
spectrum of glycan structures consisting of high mannose, hybrid, complex glycans
containing multi-antennary structures with varying level of core fucosylation and sialylation
spanning all potential N-glycosylation sites. Also observed were two PNG sites on both
1086.C gp120’s (293T and CHO cell-derived) modified with a single HexNAc on
asparagine (See Supplementary Tables 1, 2, 3 and 4). These assignments were supported
with either CID or ETD data. While this glycan is unexpected, we consistently observed N-
linked HexNAc modification on the previous glycosylation analysis of a 293T cell-derived
gp140 counterpart1 and it was also reported on the O-GlcNAcylation of postsynaptic density
pseudo-organelle derived from murine brains45.
To distinguish cell line dependent differences in the glycan profiles, glycan profile at each
site were evaluated for high mannose or processed (hybrid and complex-type) glycan
content using the criteria previously described1,37,39. The glycan profile at each site was
compared using heirarchical cluster analysis to infer the degree of similarity between the
two cell lines. Cluster analysis separates the sites with mostly processed glycans from sites
with mostly high mannose glycans. Of the 23 N-linked glycosylation sites, six sites (N230,
N241, N262, N334, and N448) were populated exclusively with high mannose glycans for
both cell lines and 16 sites were populated with mostly processed glycans. Figure 6A
summarizes the cell line dependent glycan profile for each of the 23 PNG sites of 1086.C
gp120 expressed in the two cell lines. The very short branches in the dendrogram show that
the group of sites with either processed or high mannose glycans has very low variability
indicating that the glycan profiles display very high similarity except for two sites, N386 and
N392, in the V4 region between the 1086.C gp120 expressed in CHO and 293T cell lines.
These sites were populated with high mannose glycans in the CHO cell-derived 1086.C
gp120 while a mixture of high mannose and processed glycans in the 293T cell-derived
1086.C gp120. Cluster analysis also revealed that the glycosylation sites at the beginning of
the sequence and at the end of the gp120 sequence were mostly processed while
glycosylation sites in the C2(N230, N241, and N262), C3(N334), and C4 regions were
mostly high mannose. This result is consistent with the previous glycosylation analysis of
the 1086.C gp140 counterpart of the same protein expressed in 293T stably transfected cell
line.1. However, unlike the 293T cell-derived 1086.C gp140, have more sites with higher
high mannose content compared to 293T cell-derived 1086.C gp120.
We next examined the degree of fucosylation and sialylation for both 293T and CHO cell-
derived 1086.C gp120. The degree of fucosylation for each site was determined by the sum
of fucosylated glycopeptides divided by the total number of processed glycopeptides
multiplied by 100. The results showed that the degree of fucosylation for 1086.C gp120
expressed in CHO cells was slightly higher compared to that of 1086.C gp120 expressed in
293T cells for most of the glycosylation sites (Fig. 6B). Analogous to the degree of
fucosylation, the degree of sialylation was calculated in a similar manner. In this case, the
results (Fig. 6C) showed a site-to-site variation in sialylation between the two gp120s. On
the average when all glycosylation sites were considered, the sialic acid content of 1086.C
gp120 expressed from CHO cell line was also slightly higher than 1086.C gp120 expressed
from 293T cell line compared to the CHO cell-derived gp120. Overall, the slightly higher
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fucose and sialic acid content observed for CHO cell-derived C.10186C gp120 compared to
293T cell-derived C.10186C gp120 was consistent with a previous analysis of glycosylation
on other gp120 proteins from these two cell lines46.
Finally, two additional distinct differences in the glycan profile between the two cell lines
were observed. First, the O-linked glycosylation were different between the two cell lines. In
293T cell-derived 1086.C gp120, we identified a series of cores 1, 2, and 4 O-linked
glycans, while for CHO cell-derived 1086.C gp120 only core 1 O-linked glycans were
observed. Another difference in the glycan profile is the presence of fucosylated O-linked
glycan in 293T cell-derived 1086.C gp120 but none in the CHO cell-derived 1086.C gp120.
Second is the presence of phosphorylated glycans for 1086.C gp120 expressed in CHO cells
with none detected on 293T-gp120. The mannose-6-phosphate (Man-6-P) glycan
modification was observed in six glycosylation sites spanning the sites N130, N137, N187,
and N197 in the V1-V2 region, N276 in the C2 region, and N408 in the V4 region. The
identification of Man-6-P modified gp120, in general, is particularly interesting. Man-6-Ps
are recognition motifs for two mannose-6-phosphate receptors (MPRs) that ensure the
transport proteins modified with Man-6-Ps from the trans-Golgi network to the
lysosome47,48. However, depending on the efficiency of targeting pathway, some Man-6-P
containing proteins are directed to the secretory pathway 49–51. It has recently been reported
that MPRs are used by HIV-1 for crossing the blood brain barrier 52 and they facilitate
HIV-1 replication in microglial cells 53. It is not known if native virions or CD4 T cell
surface gp160 trimers express mannose-6-phosphate; the one report on virion glycans made
no mention of the presence of mannose-6-phosphate in virion preparation 54,55. While the
role of Man-6-P on gp120 is unclear, its impact on the gp120 immunogenecity is currently
under study.
Antigenicity of 1086.C gp120 expressed in CHO versus 293T cells
Both the CHO and 293T cell line derived gp120 monomeric proteins bound well to CD4 and
showed similar level of CD4 induced 17b mAb binding (CD4i epitope). There was no
difference in the overall antigenicity of the two forms of 1086.C gp120 proteins when
assessed by comparing binding to monoclonal antibodies to C1 (A32), conformational V2
(697D, 2158), CD4 binding site (VRC01) and the carbohydrate binding bNAb 2G12 (Fig.
7). Neither of the two forms of 1086.C gp120 bound to the conformational V1/V2 bNAbs
(PG9, PG16, CH01).
Conclusions
We have demonstrated the advantage of the combination of ETD and CID for the
determination of distinct similarities and differences in the glycosylation profiles of 1086.C
gp120 expressed in CHO and 293T cells. The implementation of ETD in our workflow
facilitated the analysis and allowed the unambiguous identification of modification sites. As
a result, we have obtained full glycosylation coverage for all 23 N-linked sites for both CHO
and 293T cell-derived 1086.C gp120. The effective addition of ETD expanded the
glycosylation profile of both CHO and 293T cell-derived 1086.C gp120 with the
identification of O-linked modified sites near the end of the gp120 sequence. Indeed, the
inclusion of ETD allowed for the unambiguous elucidation of the O-glycans populating the
O-linked site for the first time. Site-to-site comparison revealed that CHO and 293T cell-
derived 1086.C gp120s display very similar glycosylation profile with few subtle
distinctions. We determined that 1086.C gp120 expressed in CHO and 293T differs in the
glycan profile in two sites in the V4 region and that the N-glycan profile of CHO cell-
derived 1086.C gp120 exclusively contains phosphorylated glycans as well as a slightly
higher degree of fucosylation and sialylation. In addition, 293T cell-derived 1086.C appears
to contain cores 1,2, and 4 O-linked glycan while exclusively core 1 O-linked glycans were
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detected in CHO cell-derived 1086.C gp120. While there was no major difference in the
antigenicity of 293T vs. CHO produced gp120s with regard to a panel of anti-HIV-1 gp120
antibodies, distinguishing host-cell specific variations in glycosylation profiles remains
important.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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1086.C gp120 sequence. Dashes indicate gaps in amino acid sequence and the location of
the variable (V1-V5) and conserved (C1-C5) regions are shown with potential glycosylation
sites in red. To standardize the sequence positions, numbering was based on the reference
HIV strain, HXB2.
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(A) LC/ESI-FTICR mass spectrum of a glycopeptide rich fraction showing glycopeptides
found in the V2-C2 region and a non-glycosylated peptide located in the V5 loop for 1086.C
gp120 expressed in CHO cells. Glycan compositions of each observed glycopeptide peak in
the mass spectra were verified from tandem MS data. Representative (B) CID spectrum
shows the glycosidic cleavages used to assign the glycan portion and (C) ETD spectrum
showing peptide backbone cleavages used to assign and confirm the peptide portion inferred
from the Y1 ion in the CID data. Asterisks (*) indicate z+1 and c+1 ions.
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CID and ETD analyses of the degree of glycosylation site occupancy. (A) CID and (B) ETD
spectra of the partially deglycosylated peptide, , with precursor
ion m/z at 1147 (2+, CID) and 765 (3+, ETD). Fragmentation pattern from both CID and
ETD data clearly indicate that the glycopeptide is occupied at N386. (C) ETD spectrum of
the glycopeptide, , with precursor ion at m/z 973 (3+) containing
complex-type glycan at N397, and (D) ETD spectrum of the glycopeptide,
, with precursor ion at m/z 1094 (4+) containing high
mannose/hybrid-type at N301 and complex-type glycans at N401. Asterisks, (*) indicates z
+1 and c+1 ions and (**) indicates z+2 and c-2 ions.
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Identification of O-linked glycopeptides by tandem MS. (A) CID and (B) ETD mass spectra
of an O-linked core-2-type glycopeptide identified from 1086.C gp120 expressed in 293T
cells. Asterisks (*) indicate z+1 and c+1 ions
Go et al. Page 17














Identification of phosphorylated glycopeptides from the tryptic digest of 1086.C gp120
expressed in CHO cells by (A) CID and (B) ETD. Cleavage of the glycosidic bond and the
peptide backbone (y3-y9) as well as loss of phosphate was observed from CID spectrum of
the phosphorylated high mannose with peptide portion, , in the V2-
C2. ETD experiments yield mainly peptide backbone cleavages c/z- type ions. Also
observed were glycosidic cleavages at m/z 1211 and 1332 resulting from additional
activation during ETD.
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(A) Comparison of the host cell specific glycan profile by hierarchical clustering using
Ward’s method linkage analysis. Two distinct clusters with respect to glycosylation were
observed. Heatmap shows the relative standardized processed glycans (z-score) using the
following color key: blue indicates processed glycans and pink indicates high mannose
glycans. (B) Comparison of the degree of fucosylation (top panel) and sialylation (bottom
panel) between 1086.C gp120 expressed in CHO and 293T cells.
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Antigenicity of 1086.C gp120 proteins grown in CHO and 293T cells.. Antigenicity was
compared by surface plasmon resonance measurements of the binding of each 1086.C gp120
protein (100 µg/mL) to HIV-1 gp120 mAbs. The gp120 conformational C1 mAb A32 (A)
was directly immobilized to the sensor chip, and the CD4i (CD4 inducible) mAb17 mAb (B)
binding was measured following capture of gp120 on a CD4 immobilized surface. Each of
the mAbs listed in the Table above and including the broadly neutralizing CD4 binding site
mAb VRC01 (C), and 2G12 (D) were captured on anti-Fc immobilized surface as described
in Methods. Specific binding of 1086.C gp120 to gp120 mAbs in Response Units were
scored as follows- no binding = −; >100 = ++; >1000 = +++.
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Table 1





No. of Sites Occupied
293T CHO
N-Linked Glycosylation
1 0 and 1 1
1 0 and 1 0 and 1
1 0 and 1 0 and 1
1 0 and 1 0 and 1
1 1 1
1 0 and 1 0 and 1
1 1 1
1 0 and 1 0 and 1
2 0, 1, and 2 0, 1, and 2
1 0 and 1 0 and 1
2 0, 1, and 2 0, 1, and 2
1 0 and 1 0 and 1
1 0 and 1 0 and 1
2 0, 1, and 2 0, 1, and 2
2 1 1
1 0 and 1 0 and 1
1 0 and 1 0 and 1
2 0 and 1 0 and 1
O-Linked Glycosylation
1 0 and 1 0 and 1
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Table 2
O-linked glycans attached to T499 in 293T and CHO cell-derived 1086.C gp120
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